Movatterモバイル変換

Aklidinijum bromid

С Википедије, слободне енциклопедије

Aklidinijum bromid
Klinički podaci

Prodajno ime	Bretaris Genuair, Eklira Genuair, Tudorza Pressair
Drugs.com	bromide.html Monografija
Način primene	Respiratorno (inhalacija)
Farmakokinetički podaci
Poluvreme eliminacije	2,4 minuta
Izlučivanje	Renalno

Identifikatori
CAS broj	320345-99-1^Да
ATC kod	R03BB05 (WHO)
PubChem	CID11519741
DrugBank	DB08897^Да
ChemSpider	9694529^Да
ChEBI	CHEBI:65344^Да
ChEMBL	CHEMBL551466^Да
Hemijski podaci
Formula	C₂₆H₃₀BrNO₄S₂
Molarna masa	564,555
SMILES [Br-].OC(C(=O)OC1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1
InChI InChI=1/C26H30NO4S2.BrH/c28-25(26(29,23-9-4-17-32-23)24-10-5-18-33-24)31-22-19-27(14-11-20(22)12-15-27)13-6-16-30-21-7-2-1-3-8-21;/h1-5,7-10,17-18,20,22,29H,6,11-16,19H2;1H/q+1;/p-1^Да Key:XLAKJQPTOJHYDR-UHFFFAOYNA-M^Да

Aklidinijum bromid jeorgansko jedinjenje, koje sadrži 26atoma ugljenika i imamolekulsku masu od 564,555Da.^[1]^[2]^[3]^[4]^[5]

Osobine

[уреди |уреди извор]

Osobina	Vrednost
Broj akceptora vodonika	4
Broj donora vodonika	1
Broj rotacionih veza	10
Particioni koeficijent^[6] (ALogP)	1,0
Rastvorljivost^[7] (logS, log(mol/L))	-7,7
Polarna površina^[8] (PSA,Å²)	155,2

Reference

[уреди |уреди извор]

^Reid, D. J.; Pham, N. T. (Print 2013).„Emerging Therapeutic Options for the Management of COPD”.Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine.7: 7—15.PMC 3629926 .PMID 23641160.doi:10.4137/CCRPM.S8140. Проверите вредност парамет(а)ра за датум:|date= (помоћ)
^Cazzola, M.; Page, C. P.; Matera, M. G. (Epub 2013 Apr 9). „Aclidinium bromide for the treatment of chronic obstructive pulmonary disease”.Expert Opinion on Pharmacotherapy.14 (9): 1205—1214.PMID 23566013.S2CID 24973904.doi:10.1517/14656566.2013.789021. Проверите вредност парамет(а)ра за датум:|date= (помоћ)
^Jones, P. (Epub 2013 Apr 2). „Aclidinium bromide twice daily for the treatment of chronic obstructive pulmonary disease: A review”.Advances in Therapy.30 (4): 354—368.PMID 23553509.S2CID 3530290.doi:10.1007/s12325-013-0019-2. Проверите вредност парамет(а)ра за датум:|date= (помоћ)
^Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011).„DrugBank 3.0: A comprehensive resource for 'Omics' research on drugs”.Nucleic Acids Research.39 (Database issue): D1035—D1041.PMC 3013709 .PMID 21059682.doi:10.1093/nar/gkq1126.
^Wishart, David S.; Knox, Craig; Guo, An Chi; Cheng, Dean; Shrivastava, Savita; Tzur, Dan; Gautam, Bijaya; Hassanali, Murtaza (2008).„DrugBank: A knowledgebase for drugs, drug actions and drug targets”.Nucleic Acids Research.36 (Database issue): D901—D906.PMC 2238889 .PMID 18048412.doi:10.1093/nar/gkm958.
^Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”.The Journal of Physical Chemistry A.102 (21): 3762—3772.Bibcode:1998JPCA..102.3762G.doi:10.1021/jp980230o.
^Tetko, Igor V.; Tanchuk, Vsevolod Yu.; Kasheva, Tamara N.; Villa, Alessandro E. P. (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”.Journal of Chemical Information and Computer Sciences.41 (6): 1488—1493.PMID 11749573.doi:10.1021/ci000392t.
^Ertl, Peter; Rohde, Bernhard; Selzer, Paul (2000). „Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties”.Journal of Medicinal Chemistry.43 (20): 3714—3717.PMID 11020286.doi:10.1021/jm000942e.